Lupus Nephritis

This research into obinutuzumab may provide some hope for those facing the most common cause of kidney damage among patients with lupus.

An analysis of data from 26 patients with repeat kidney biopsies in the AURORA program suggests voclosporin (Lupkynis) reduces proteinuria without causing harm in lupus nephritis patients.

Significantly more patients receiving voclosporin had a good renal outcome, defined as achieving adequate response with no renal flare, compared with controls.

Most patients with lupus nephritis reported moderate anxiety and moderate depression which impacted their disease activity and quality of life.

An analysis of data from the phase 2 AURA-LV and phase 3 AURORA 1 trials provides new insight into the effects of voclosporin for the treatment of active lupus nephritis in patients with high proteinuria.

An analysis of data obtained from urine samples in the MUSE and TULIP-1 trial sheds new light on the clinical utility of the RAIL score for identifying disease activity and treatment responders in SLE patients with and without lupus nephritis, respectively

Data from an analysis of kidney biopsies from the AURORA 2 trial presented at CCR East 2023 offer new insight into the long-term histological impact of voclosporin use on renal function in patients with lupus nephritis.

Alfredo Aguirre, MD, discusses the latest data regarding lupus this year at the American College of Rheumatology (ACR) Convergence 2022, trends in lupus management, and the importance of remission in lupus.

A significantly higher number of patients receiving voclosporin achieved good renal outcome when compared with placebo.

Drs. Anne E. Winkler and Kristi V. Mizelle share practice pearls to optimize the management of patients of patients diagnosed with lupus.

"Lupus nephritis (LN) patients might suffer from mental disorders which further prolong the LN treatment duration and affect patients' quality of life.”

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 3, 2022.

Previous renal response endpoints used in lupus nephritis trials lacked uniformity and their accuracy of long-term kidney survival prediction was questionable.

"An unmet need is a biomarker that distinguishes active lupus nephritis, particularly important in pediatrics where minimizing invasive procedures is desirable.”

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 30, 2022.

The US FDA has approved belimumab for the treatment of active lupus nephritis in children aged 5 to 17 who are currently receiving standard therapy.

The utility of calculating interferon scores in SLE has generated considerable discourse amongst rheumatologists.

Anne Winkler, MD, discusses the importance of patient-reported outcome measures when treating her patients with lupus.

Anne Winkler, MD, discusses her upcoming CCR East presentation, “Targeting Lupus Nephritis.”

In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.

Telemedicine is an evolving and helpful tool in how rheumatologists manage their outpatient cohort. However, careful distinction of who can continue to be managed remotely is crucial.

With several targeted therapies demonstrating positive trial results in lupus nephritis, the treatment paradigm appears to be shifting.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 25, 2021.

Study provides supportive data to confirm the pathogenic role of NEU1 in proliferative lupus nephritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 11, 2021.